Trastuzumab inhibits pituitary tumor cell growth modulating the TGFB/SMAD2/3 pathway

Abstract

In pituitary adenomas, early recurrences and resistance to conventional pharmacotherapies are common, but the mechanisms involved are still not understood. The high expression of epidermal growth factor receptor 2 (HER2)/extracellular signal-regulated kinase (ERK1/2) signal observed in human pituitary adenomas, together with the low levels of the antimitogenic transforming growth factor beta receptor 2 (TBR2), encouraged us to evaluate the effect of the specific HER2 inhibition with trastuzumab on experimental pituitary tumor cell growth and its effect on the antiproliferative response to TGFB1. Trastuzumab decreased the pituitary tumor growth as well as the expression of ERK1/2 and the cell cycle regulators CCND1 and CDK4. The HER2/ERK1/2 pathway is an attractive therapeutic target, but its intricate relations with other signaling modulators still need to be unraveled. Thus, we investigated possible cross-talk with TGFB signaling, which has not yet been studied in pituitary tumors. In tumoral GH3 cells, co-incubation with trastuzumab and TGFB1 significantly decreased cell proliferation, an effect accompanied by a reduction in ERK1/2 phosphorylation, an increase of SMAD2/3 activation. In addition, through immunoprecipitation assays, a diminution of SMAD2/3-ERK1/2 and an increase SMAD2/3-TGFBR1 interactions were observed when cells were co-incubated with trastuzumab and TGFB1. These findings indicate that blocking HER2 by trastuzumab inhibited pituitary tumor growth and modulated HER2/ERK1/2 signaling and consequently the anti-mitogenic TGFB1/TBRs/SMADs cascade. The imbalance between HER2 and TGFBRs expression observed in human adenomas and the response to trastuzumab on experimental tumor growth may make the HER2/ERK1/2 pathway an attractive target for future pituitary adenoma therapy.

Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways

“…No significant difference was highlighted for TGF-β RI [133]. The same conclusion was drawn by Petiti et al [134], who also demonstrated that when incubated with trastuzumab, PitNET cell proliferation was inhibited via an enhanced expression of Smad2 and Smad3. This suggests that the TGF-β pathway is far more complex than previously believed, including the EGFR/Erk pathway (which, when activated, reduces Smad2 and Smad3 phosphorylation).…”

Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence

“…Immunoprecipitation of HER2 in normal and transformed epithelial cells was coimmunoprecipitated with the cadherin‐catenin complex, revealing a HER2 and β‐catenin in association with the basal condition . The connection between HER2 and SMAD3 independent of TGF‐β receptor might be regulated through β‐catenin/Smad3 colocalization …”

TGF-β Signaling Pathway-Based Model to Predict the Subtype and Prognosis of Head and Neck Squamous Cell Carcinoma

“…TGF-β comprises a family of growth factors, which play crucial roles in development, fibrosis, and cancer progression ( Nüchel et al, 2018 ). TGF-β binding activates type II and then type I receptors, that in turn activate an increase of SMAD signals activation ( Petiti et al, 2018 ; Lähde et al, 2021 ). Studies have demonstrated that high cancer-associated fibroblast infiltrated gastric cancer is associated with immunosuppressive microenvironment regarding to TGF-β alterations ( Liu et al, 2021 ).…”